pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › BBIO

BBIO PDUFA Date: BBP-418

FDA decision (PDUFA) target 2026-11-27 · BridgeBio Pharma Inc. · Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)

BBIO run-up into the PDUFA (last ~120 days)

$77.93$63.88
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-11-27
Drug / candidateBBP-418
IndicationLimb Girdle Muscular Dystrophy Type 2i (LGMD2i)
CompanyBridgeBio Pharma Inc.
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.govNCT05775848 · Fast Track Designation (FTD), Rare Pediatric Disease designation

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the BBIO PDUFA date?
The FDA PDUFA target date for BBIO (BridgeBio Pharma Inc.) is 2026-11-27 for BBP-418. Dates are company/FDA-sourced and can slip — verify against primary filings.
What is BBIO's drug BBP-418?
BBP-418 is BridgeBio Pharma Inc.'s candidate under FDA review for Limb Girdle Muscular Dystrophy Type 2i (LGMD2i).
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.